Two new compounds with anticancer and antibacterial activities purified from LZC03.

In the course of investigating endophytic fungi derived from medicinal plants, a fungal strain identified as (designated LZC03) was successfully isolated from R. Brown. Comprehensive chemical analysis of its fermentation metabolites, employing a series of chromatographic separation techniques, led to the isolation and structural characterisation of two previously undescribed compounds: ()-(+)-methyl-5-(3,4-dihydroxybutyl) picolinate (), ()-(+)-butyl -5-(3,4-dihydroxybutyl) picolinate (), and one known compound, ()-(+)-methyl fusarinolate (). Compounds and demonstrated moderate cytotoxic effects against the HCT-116 human colon cancer cell line, with IC values of 59.27 and 55.86 μg/mL, respectively. Compounds exhibited differential inhibitory effects against (CMCC(B)26003), (CMCC(B)63534), (CMCC(B)44102), and (CMCC(B)10104), and predominantly targeted Gram-positive strains. Moreover, compounds and exhibited significant antibacterial activity against , with minimum inhibitory concentrations (MICs) lower than that of the reference drug, suggesting their potential as bifunctional bioactive agents.